MPR group:None

2 trials

Sponsors

Shanghai Pulmonary Hospital, Fujian Medical University Union Hospital

Conditions

NSCLCNon-small cell lung cancer

Phase 2

Efficacy of PD-1 inhibitor combination therapy in non-small cell lung cancer patients who have not achieved major pathologic response after neoadjuvant immunotherapy

Active, not recruitingChiCTR2400091455

Shanghai Pulmonary HospitalNSCLC

Start: 2024-10-31Updated: 2024-11-04

Unknown Phase

Adjuvant Therapy Optimization Guided by Major Pathological Response: A Multicenter Retrospective Analysis in Non-Small Cell Lung Cancer after Neoadjuvant Treatment

Active, not recruitingChiCTR2500109490

Fujian Medical University Union HospitalNon-small cell lung cancer

Start: 2025-10-01Updated: 2025-09-22